Table 2.
Complications and adverse events secondary to IVT injections performed by one surgeon, compared with ranibizumab and pegaptanib clinical trials (incidence per patient)
| Complications | Our study n = 59 | Rosenfeld, MARINA study16 n = 477 | Regillo, PIER study10 n = 120 | Eyetech study, Phase II8 n = 21 | D’Amico, VISION study, Year 19 n = 892 | D’Amico, VISION study, Year 29 n = 606 |
|---|---|---|---|---|---|---|
| Lid swelling | 1.7% | N/A | N/A | 14.3% | N/A | N/A |
| Vitreous floaters | 1.7% | N/A | N/A | 19.0% | 33% | 24% |
| RPE tear | 1.7% | 0.4% | 0 | N/A | N/A | N/A |
| Corneal edema | 1.7% | N/A | N/A | N/A | 10% | 9% |
| Corneal abrasion | 1.7% | N/A | N/A | 14.3% | N/A | N/A |
| Transient NLP | 8.5% | N/A | N/A | N/A | N/A | N/A |
| Arterial thrombotic events | 0 | 3.8% | 0 | N/A | 3% | 2% |
| Endophthalmitis | 0 | 1.0% | 0 | N/A | 1.3% | 0.6% |
| Retinal detachment | 0 | 0 | 0 | 4.8% | 0.7% | 1.2% |
| Traumatic cataract | 0 | 0.2% | 0 | 0 | 0.6% | 0.2% |
| Vitreous hemorrhage | 0 | 0.4% | 0 | N/A | 1.8% | 1.8% |
Abbreviations: IVT, intravitreal; RPE, retinal pigment epithelial; N/A, not applicable; NLP, no light perception.